News Medical

Alpha particle therapy offers new hope for neuroendocrine tumors

In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...
WNCT

Alpha particle therapy emerges as a potent weapon against neuroendocrine tumours

Drs. Kalyan M. Shekhda1 (Royal Free Hospital, London, UK), Shaunak Navalkissoor Royal Free Hospital, London, UK), and Ashley B. Grossman (University of Oxford and Queen Mary University of London, ...
Seeking Alpha

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (Lantheus) today announced it has entered into multiple strategic agreements with Perspective Therapeutics, Inc.
KHON2

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European ...

[212 Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumors Administration of fractionated doses of [212 Pb]VMT-α-NET shows 100% survival in a robust model of metastatic ...
Seeking Alpha

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a ...
Nasdaq

Perspective Therapeutics, Inc. Initiates First Patient Dosing in Phase 1/2a Trial of [212Pb]VMT01 for Melanoma Treatment

Perspective Therapeutics, Inc. announced the dosing of the first patient in a new cohort of its Phase 1/2a trial assessing the safety of [212Pb]VMT01, a targeted alpha-particle therapy for melanoma ...
KXAN

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive ...

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at ...